Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702844 | 1.00 | ADRB2 (0.66) | ADRB2HTR6HTR2AHTR1AHTR2C | |
| SCHEMBL18028919 | 0.83 | ADRB2 (0.59) | ADRB2HTR6MTNR1AMTNR1BNQO2 | |
| SCHEMBL20024496 | 0.81 | HTR2C (0.43) | ADRB2HTR6HTR2AHTR1AHTR2C | |
| SCHEMBL13888101 | 0.80 | ADRB2 (0.70) | ADRB2HTR6MTNR1AMTNR1BNQO2 | |
| SCHEMBL1130016 | 0.79 | ADRB2 (1.00) | ADRB2HTR6HTR2AHTR1AHTR2C | |
| SCHEMBL623472 | 0.79 | HTR2C (0.51) | ADRB2HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL30520734 | 0.79 | HTR2C (0.51) | ADRB2HTR2AHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7680700 | 0.78 | ADRB2 (0.97) | ADRB2HTR6HTR2AHTR1AHTR2C | |
| SCHEMBL12185393 | 0.78 | ADRB2 (0.76) | ADRB2HTR6MTNR1AMTNR1BNQO2 | |
| SCHEMBL6261747 | 0.78 | ADRB2 (0.67) | ADRB2HTR6MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | claimed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | claimed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | claimed |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | claimed |
| US-20200397721-A1 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder | UNIV DREXEL (US) | 2020-12-24 | — | — | US | claimed |
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2020-12-17 | — | — | US | claimed |
| EP-3062791-B1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2020-01-08 | — | — | EP | claimed |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2018-04-05 | — | — | US | claimed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | claimed |
| EP-3062791-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | Drexel University (US) | 2016-09-07 | — | — | EP | claimed |
| WO-2015066019-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2015-05-07 | — | — | WO | claimed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | claimed |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | disclosed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | disclosed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | ADRB2 73/4885HTR6 184/4885HTR2A 129/4885 |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, COMT, SLC6A2 | ADRB2 1440/4885HTR6 86/4885HTR2A 71/4885 |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DRD3, PARK7, SLC6A3 | ADRB2 56/4885HTR6 177/4885HTR2A 121/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | ADRB2 73/4885HTR6 184/4885HTR2A 129/4885 |
| US-20200397721-A1 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder | CHAT, COMT, SLC6A2 | ADRB2 1440/4885HTR6 86/4885HTR2A 71/4885 |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | ADRB2 2151/4885HTR6 97/4885HTR2A 82/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | ADRB2 2151/4885HTR6 97/4885HTR2A 82/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | ADRB2 570/4885HTR6 125/4885HTR2A 51/4885 |
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | CHAT, COMT, SLC6A2 | ADRB2 1440/4885HTR6 86/4885HTR2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.